J.P. Morgan Natural Capital and the Paraguayan government announced a $200 million investment to develop a sustainable forestry platform in Paraguay. Partnering with Grupo Robinson, the project aims to establish commercial forests, restore native forests, and create value through timber, carbon credits, and wood products. The initiative supports Paraguay's industrialization by processing timber locally, creating jobs, and strengthening rural communities. Capital deployment will start in early 2027, promising significant economic and regional benefits.
The $200 million sustainable forestry investment by the Office of the President of Paraguay and J.P. Morgan Asset Management provides context for resource sector interest. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 25, 2026 01:41 WIB: Of 38 priced US stocks, 6 rose and 32 fell. Notable movers include NEM at USD 121.00 with a 1-day change of -2.06% and 97% buy order activity, CF at USD 118.38 with a -1.90% change and 100% buy order activity, and ICL at USD 5.20 with a -1.89% change and 100% buy order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
